Steven F. Bellon
Foghorn Therapeutics (United States)(US)
Publications by Year
Research Areas
Chromatin Remodeling and Cancer, Protein Degradation and Inhibitors, Liver physiology and pathology, PI3K/AKT/mTOR signaling in cancer, Cancer Mechanisms and Therapy
Most-Cited Works
- → DNA unwinding produced by site-specific intrastrand crosslinks of the antitumor drug cis-diamminedichloroplatinum(II)(1991)292 cited
- → The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity(2005)258 cited
- → Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas(2016)218 cited
- → Crystal Structures of Escherichia coli Topoisomerase IV ParE Subunit (24 and 43 Kilodaltons): a Single Residue Dictates Differences in Novobiocin Potency against Topoisomerase IV and DNA Gyrase(2004)156 cited
- → Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-[Pt(NH3) 2 (N3-cytosine) Cl]+(1990)147 cited
- → Crystal structure of the RAG1 dimerization domain reveals multiple zinc-binding motifs including a novel zinc binuclear cluster(1997)145 cited
- → Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase(2008)139 cited
- → c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations(2007)137 cited
- → Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin(1990)132 cited
- → Structure-Based Design of Novel Class II c-Met Inhibitors: 1. Identification of Pyrazolone-Based Derivatives(2012)102 cited